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doi:10.1016/j.jfma.2012.02.016Background/Purpose: Anticoagulation is underused for stroke patients with atrial fibrillation in
Taiwan. An effective preventive measure is in great need of improvement.
Methods: In-hospital case management was implemented to monitor the diagnosis of atrial
fibrillation and the use of warfarin. Timely feedback to treating physicians was made. Change
in performance after the implementation was analyzed.
Results: A total of 2754 patients hospitalized for acute ischemic stroke or transient ischemic
attack were included, 1216 before and 1538 after the intervention. The percentage of
patients without electrocardiography examination decreased from 8.7% to 2.9%
(p < 0.001). The diagnosis of atrial fibrillation increased from 11.5% (n Z 140) to 15.9%
(n Z 244) (p Z 0.001). The use of warfarin at discharge increased from 36.9% to 54.7%
(p Z 0.001). In-hospital case management was significantly related to the use of warfarin
(odds ratio Z 2.47, p < 0.001). The percentage of warfarin use was still significantly higher
in the intervention group at 3 months of follow-up (45.9% vs. 27.8%, p Z 0.002) and at 6
months of follow up (49.2% vs. 28.6%, p Z 0.004). More patients’ international normalized
ratio was within the recommended range in the intervention group at 6 months’ follow-up
(30.5% vs. 9.1%, p Z 0.039).
Conclusion: Our study indicates that in-hospital case management may be an effective
strategy to improve anticoagulation for eligible stroke patients.
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Atrial fibrillation is an important risk factor for ischemic
stroke.1 The use of anticoagulation is recommended for
strokeprevention in guidelines2,3 andperformancemeasures
of stroke care.4e7 However, the guideline recommendations
that anticoagulation should be provided in accordance with
stroke risk in atrial fibrillation patients are not routinely
followed in clinical practice.8e10
In the Taiwan Stroke Registry (TSR), a reduction in the
risk of cardiovascular events and death within 1, 3, and 6
months post-stroke is noted in patients with atrial fibrilla-
tion who received anticoagulation at discharge as
compared to those who did not receive it. However, only
28.28% Taiwanese stroke patients with atrial fibrillation
were prescribed warfarin.11 An urgent and effective
preventive measure is in great need of improvement.
The Case Management Society of America defines case
management as “a collaborative process which assesses,
plans, implements, coordinates, monitors, and evaluates
options and services to meet and individual’s health needs
through communications and available resources to promote
quality cost-effective outcomes.”12 An in-hospital case
management strategy may facilitate the improvement of
qualityof care for acute stroke,especially inamedical center
with complex infrastructures. We report the change of anti-
coagulation therapy for stroke patients with atrial fibrillation
after the implementation of this strategy in our hospital.
Methods
Changhua Christian Hospital (CCH) is a participant in the
nationwide TSR that enrolled acute stroke patients after
a written informed consent obtained.11 The Institutional
Review Board at CCH approved this study for human partici-
pants. There is no stroke unit in the hospital. Neurologists and
neurosurgeons care for stroke patients in the neurologyward,
the neurosurgery ward, the neurological intensive care unit,
and the surgical intensivecareunit. Twostrokecasemanagers
(senior nursing staffs)were appointed tomonitor and improve
the quality of stroke care in the hospital. They coordinated
treating teammeetings and implemented improvement plans
that were based on guideline recommendations. Specifically
for performance indicator of anticoagulation for atrial fibril-
lation, a preprinted form, “CCH Strokedatrial fibrillation”
(CCHStroke-AF; Fig. 1),was designedbased on the congestive
heart failure, history of hypertension, age 75 years or older,
diabetes mellitus, prior cerebral ischemia (CHADS2) risk
stratification13 and used for patients with acute ischemic
stroke or transient ischemic attack since January 2009.
Physicians in charge of caring for stroke patients were
instructed to fill out and sign the CCH Stroke-AF form. There
was no other educational program for physicians.
Stroke case managers recorded the use of electrocardi-
ography (EKG) and CCH Stroke-AF. A 12-lead EKG exami-
nation was recommended for every registered patient
during admission. Definition of atrial fibrillation includes
a history of the diagnosis, atrial fibrillation in a previous
EKG, or atrial fibrillation that was found during admission.
Treating physicians of patients with acute ischemic stroke
or transient ischemic attack were notified by phone calls ifeligible patients did not receive EKG examination or CCH
Stroke-AF form was not used in the medical record for
eligible patients. Warfarin use was defined as using
warfarin at discharge. Reasons for not using warfarin were
left to the treating physician, but it was recommended to
document this information in the CCH Stroke-AF form.
Hospitalized patients between January 2008 and April
2010 were included for this analysis. Registered patients
before and after January 2009 were grouped as before and
after intervention, respectively. Characteristics of
patients, including the use of EKG examination, frequency
of atrial fibrillation, and frequency of warfarin use for atrial
fibrillation were compared between the two groups.
Change in performance and reasons for not using warfarin
after the implementation were analyzed. Independent
factors related to warfarin use at discharge in atrial fibril-
lation patients who survived the stroke were analyzed by
multivariate analysis. Statistical analyses were performed
with SPSS for Windows, version 13.0. We used c2 tests to
compare dichotomous variables, and unpaired, two-tailed
t-tests were used to compare continuous variables. All
statistically significant levels were defined as p < 0.05.Results
A total of 2754 patients hospitalized for acute ischemic
stroke or transient ischemic attack were included in this
analysis, 1216 before and 1538 after the intervention. The
characteristics of patients in the two groups are presented
in Table 1. The percentage of patients without EKG exam-
ination significantly decreased from 8.7% to 2.9%
(p < 0.001) after the intervention. Atrial fibrillation was
found in 11.5% (n Z 140) before and 15.9% (n Z 244)
patients after the intervention (p Z 0.001).
The characteristics of patients with atrial fibrillation in
the two groups are shown in Table 2. In the group after
intervention, mean age was older and there were more
females, but these differences were not statistically
significant. The use of warfarin at discharge significantly
increased after the intervention, from 36.9% to 54.7%
(p Z 0.001). The international normalized ratio (INR) of
prothrombin time test for warfarin users before discharge
was performed more frequently after intervention, from
75% to 94.9% (p < 0.001). INR results were similar between
the two groups. Mortality was 7.1% before and 12.3% after
the intervention (p Z 0.109). The use of warfarin in
mortality participants was 10% in both groups (1 in 10 and 3
in 30, before and after intervention, respectively).
Twenty-two patients after the intervention did not use
warfarin without a documented reason (13.7%, 22 in 127).
Documented reasons for not using warfarin are shown in
Table 3. The most frequent reason was a concern of
bleeding risk (41.7%, 53 in 127).
Table 4 shows the results of warfarin use and INR at 3
and 6 months’ follow-up. The percentage of warfarin use
was still significantly higher in the intervention group at 3
months’ follow-up (45.9% vs. 27.8%, p Z 0.002) and at 6
months’ follow up (49.2% vs. 28.6%, p Z 0.004). More
patients’ INR was within the recommended range (between
2 and 3) in the intervention group at 6 months’ follow-up
(30.5% vs. 9.1%, p Z 0.039).
Figure 1 A sample form of Changhua Christian Hospital Strokedatrial fibrillation.
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independent variables related to warfarin use at discharge
in atrial fibrillation patients who survived the stroke
(nZ 344). Increased age was negatively related to the use
of warfarin (p Z 0.020). History of previous stroke was
related to the use of warfarin (pZ 0.017). Intervention was
significantly related to the use of warfarin (odds
ratio Z 2.47, p < 0001).Discussion
In Taiwan, the use of warfarin in stroke patients with
atrial fibrillation based on guideline recommendation is
considerably less than that in the Get With the Guidelines-
Stroke (GWTG-Stroke) program, especially when the impact
of anticoagulation on outcomes is favorable.11 Another
Taiwanese nationwide study including 39,541 identified
Table 1 Characteristics of all patients with ischemic







Total cases 1216 1538
Age 68.7  12.6 69.712.9 0.053
Male sex 714 (58.7) 876 (57.0) 0.443
Hypertension 981 (80.7) 1228 (79.8) 0.515
Diabetes 448 (36.8) 602 (39.1) 0.230
Previous stroke 387 (31.8) 444 (28.9) 0.090
NIHSS score 8.3  8.7 8.1  8.0 0.444
Death 48 (3.9) 58 (3.8) 0.820
EKG not examined 106 (8.7) 45 (2.9) <0.001
Atrial fibrillation 140 (11.5) 244 (15.9) 0.001
NIHSS Z National Institutes of Health Stroke Scale.




Bleeding risk 53 41.7
Gastrointestinal 29 22.8
Intracranial 16 12.6
Urinary tract 3 2.4
Others 5 3.9
Death 27 21.3
Large area infarct 11 8.7
Patient/family refusal 10 7.9
Being discharged to another hospital 4 3.1
Reasons not documented 22 17.3
266 M.-C. Sun, P.-J. Hsiaopatients with atrial fibrillation, where 70.3% were at high
risk for thromboembolic events and 18.3% were at highest
risk, reported that only 24.7% of the population received
appropriate antithrombotic therapy.14 Bleeding risk is the
most common reason for not using warfarin. It has been
shown that doctors’ knowledge and awareness of the
results of recent clinical trials affect the appropriate use of
antithrombotic drug in atrial fibrillation.15 The lower rates
of EKG examination and use of warfarin before intervention
in our study suggest that this barrier to quality of stroke
care exist in the hospital. A lower prevalence of atrial
fibrillation before intervention in our patients (11.5%) than
in the TSR report (16.5%) supports the hypothesis that some
patients were not completely surveyed for risk of stroke.Table 2 Characteristics of patients with atrial fibrillation






Total cases 140 244
Age 74.5  9.5 76.7  10.9 0.070
Male sex 78 (55.7) 114 (46.7) 0.097
Hypertension 116 (82.9) 205 (84.0) 0.634
Diabetes 47 (33.6) 76 (31.1) 0.628
Previous stroke 53 (37.9) 70 (28.7) 0.068
Warfarin use at admission 16 (12.3) 27 (12.6) 0.933
INR 2e3 at admissiona 2 (12.5) 1 (3.7) 0.545
NIHSS score 13.7  9.8 13.2  10.0 0.610
mRS score at discharge 3.4  1.5 3.2  1.6 0.324
Warfarin use at dischargeb 48 (36.9) 117 (54.7) 0.001
INR checked
in warfarin users
36 (75.0) 111 (94.9) <0.001
INR 1.8  0.7 1.7  0.7 0.657
Death 10 (7.1) 30 (12.3) 0.109
a Number (percentage) of patients who had an INR between 2
and 3 in those who used warfarin at admission.
b Number (percentage) in survivors.
INR Z international normalized ratio of prothrombin time;
mRS Z modified Rankin scale.Markedly increased adherence to stroke performance
measures, including anticoagulation for atrial fibrillation
was shown in the GWTG-Stroke program.16 On the contrary,
there was no change in rate of anticoagulation for atrial
fibrillation in the TSR.11 The difference may suggest that an
intervention program, such as GWTG-Stroke, rather than
a registry is necessary for stroke care improvement. There
is evidence that even with data feedback, quality
improvement of stroke care by chart audit is not signifi-
cant.17 Our findings demonstrate that intervention by in-
hospital case management led to a 38.3% increase in diag-
nosis of atrial fibrillation and a 48.2% increase in adherence
to evidence-based performance measure.
Direct comparison of warfarin use for stroke patients
among reported results in the literature is difficult. There
are a number of reasons for excluding patients from the
eligible population.7,16 In the GWTG-Stroke program,
documented reasons for nontreatment include excessive
risk of adverse reaction, patient/family refusal, being dis-
charged to another short-term general hospital, or leave
against medical advice. Anticoagulant use in eligibleTable 4 Warfarin use and international normalized ratio






Total cases 130 214
3 mo follow-up
Death 5 (3.8) 7 (3.3) 0.778
Loss of follow-up 17 (13.1) 26 (12.1) 0.801
N of follow-up 108 (83.1) 181 (84.6) 0.712
Warfarin use 30 (27.8a) 83 (45.9a) 0.002
INR 2e3 6 (20.0b) 16 (19.3b) 0.932
6 mo follow-up
N of follow-up 77 (59.2) 120 (56.1) 0.566
Warfarin use 22 (28.6a) 59 (49.2a) 0.004
INR 2e3 2 (9.1b) 18 (30.5b) 0.039
a Percentage in follow-up patients.
b Percentage in warfarin users.
INR Z international normalized ratio of prothrombin time.
Table 5 Multivariate analysis of independent variables related to warfarin use at discharge in atrial fibrillation patients who
survived the stroke (n Z 344).
b Standard error Odds ratio 95% confidence interval p
Age 0.026 0.011 0.97 0.951.00 0.020
Male sex 0.225 0.241 1.25 0.78e2.01 0.352
Hypertension 0.459 0.322 1.58 0.84e2.97 0.155
Diabetes 0.323 0.255 1.38 0.84e2.28 0.205
Previous stroke 0.588 0.246 1.80 1.11e2.92 0.017
NIHSS score e0.023 0.013 0.98 0.95e1.00 0.064
Intervention 0.905 0.256 2.47 1.50e4.09 <0.001
Constant 0.943 0.756 d d d
NIHSS Z National Institutes of Health Stroke Scale.
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84.2% per GWTG-Stroke and might be higher if reasons of
nontreatment were documented in the 22 patients after
intervention. In the German Stroke Registers Study Group,
the eligible population for this quality indicator is limited to
patients who are discharged home or to an inpatient
rehabilitation unit and who are mobile (Barthel Index item
“Transfer” 10e15 and Barthel Index item “Mobility” 10e15)
and minor disabled (Rankin Scale 0e3) at discharge.7 Other
reports did not impose too many limits to the eligible
population; the rate of anticoagulant use was much lower
than the GWTG-Stroke result.6,18
Bleeding risk is the most common concern for nontreat-
ment in our study. Large infarct is the second one, since
a large infarct is an important predictor of symptomatic
hemorrhagic transformation.19,20 Fear of iatrogenic
hemorrhage is one of the most important reasons why
physicians do not prescribe warfarin for patients with atrial
fibrillation. However, some risk factors for stroke in atrial
fibrillation are also associated with a higher risk for
anticoagulation-associated hemorrhage.21 For example, age
and history of stroke increase both risk of stroke according
to the CHADS2 stratification13 and risk of anticoagulation-
associated hemorrhage according to the HAS-BLED (Hyper-
tension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly) stratification.21 In the results of our multi-
variate analysis, the relation between the two risk factors
and warfarin use was the opposite. The results indicate
that our physicians’ interpretation on the two factors
for warfarin use was different. This may suggest that
there is a need for a more delicate method to balance
the benefit and risk of this treatment for clinical practice.
Our study has several limitations. The interpretation of
reasons for not using warfarin, such as bleeding risk, was
left to the treating physician. Some bleeding risks might not
be considered contraindication to warfarin use. Therefore,
the documented reasons were not analyzed in the multi-
variate analysis. A single-center experience could not be
generalized because of different organizational cultures. In
addition, case managers’ roles and functions might be
difficult to define.22 They may be involved in any part of the
care process. Based on the existing guidelines and perfor-
mance measures for stroke, we believe that stroke case
managers could play an important role in quality improve-
ment of in-hospital stroke care.In conclusion, our study indicates that in-hospital case
management may improve the diagnosis of atrial fibrillation
andadherence to this evidence-basedperformancemeasure.References
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